Skip to main content
SpringerLink
Log in

Orbital and Periorbital Side Effects of Chemotherapy

  • Chapter
  • First Online:
Ophthalmic Oncology

Part of the book series: M.D. Anderson Solid Tumor Oncology Series ((MDA,volume 6))

Abstract

In this chapter, the side effects of chemotherapeutic agents on the orbit and periorbital structures, such as the eyelids, eyelashes, eyebrows, and conjunctiva, are discussed. Chemotherapy can affect these structures when it is administered topically for local disease, via selective ophthalmic artery infusion for regional disease in the orbit, or systemically for more diffuse metastatic disease or as adjuvant treatment. Systemic administration of chemotherapy often affects the eye, as drugs commonly are secreted into the tears, thereby causing local affects directly. With the exception of a few better documented side effects, the majority of side effects listed in this chapter are from small case series and anecdotal case reports. This may be a result of the rarity of side effects or of underreporting, as there are often other side effects or issues that take precedence in cancer patients. Additionally, many chemotherapeutic regimens involve more than one agent, and in such cases it is difficult to determine which agent is responsible for side effects. One must also consider a possible synergistic effect of multiple drugs. The text of this chapter is organized by drug, whereas the tables are organized by side effect, to allow practitioners to look up clinically observed side effects and attempt to determine the offending agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Registry of Drug-Induced Ocular Side Effects. http://www.eyedrugregistry.com/. Accessed November 2008.

  2. Fraunfelder FW, Fraunfelder FT. Drug-induced ocular side effects: oncolytic agents. In: Fraunfelder FT, Fraunfelder FW, Chambers WA, editors. Clinical Ocular Toxicology. Philadelphia, PA: Elsevier, 2008:199–221.

    Google Scholar 

  3. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology 1983;90:1–3.

    PubMed  CAS  Google Scholar 

  4. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic chemotherapy. Surv Ophthalmol 1989;34(3):209–30.

    Article  PubMed  CAS  Google Scholar 

  5. Schmid KE, Kornek GV, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006;51:19–40.

    Article  PubMed  Google Scholar 

  6. Chrousos GA, Oldfield EH, Doppman JL, et al. Prevention of ocular toxicity of carmustine (BCNU) with supraophthalmic intracarotid infusion. Ophthalmology 1986;93:1471–5.

    PubMed  CAS  Google Scholar 

  7. Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985;92:402–6.

    PubMed  CAS  Google Scholar 

  8. Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003;42:345–6.

    Article  PubMed  Google Scholar 

  9. Bouche’ O, Brixi-Benmansour H, Bertin A, et al. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1711–2.

    Article  Google Scholar 

  10. Giuseppe T, Vicenzi B, Santini D, et al. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst 2005;97:606–7.

    Article  Google Scholar 

  11. Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol 1993;116(4):508–9.

    PubMed  CAS  Google Scholar 

  12. Kaya AO, Buyukberber S, Coskun U, et al. Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer. Cutan Ocul Toxicol 2008;27:327–31.

    Article  PubMed  CAS  Google Scholar 

  13. Marquez G, Herrera-Acosta E, Vidal I, et al. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol 2009;48(1):97–8.

    Article  PubMed  Google Scholar 

  14. Lane K. Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23(1):65–66.

    Article  PubMed  Google Scholar 

  15. Lauer AK, Wobig JL, Shults WT, et al. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol 1999;127(2):230–3.

    Article  PubMed  CAS  Google Scholar 

  16. Forbes JE, Brazier DJ, Spittle M. 5-Fluorouracil and ocular toxicity. Br J Ophthalmol 1993;77(7):465–6.

    Article  PubMed  CAS  Google Scholar 

  17. Hurwitz BS. Cicatricial ectropion: a complication of systemic fluorouracil. Arch Ophthalmol 1993;111:1608–9.

    Article  PubMed  CAS  Google Scholar 

  18. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002;95:881–7.

    Article  PubMed  Google Scholar 

  19. Grossman WJ, Wilson DB. Hypopigmentation from imatinib mesylate (Gleevec). J Pediatr Hematol Oncol 2004;26:214.

    Article  PubMed  Google Scholar 

  20. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19:371–5.

    Article  PubMed  CAS  Google Scholar 

  21. Schaich M, Schakel K, Illmer T, et al. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003;82:303–4.

    PubMed  CAS  Google Scholar 

  22. Esmaeli R, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye 2004;18(7):760–2.

    Article  PubMed  CAS  Google Scholar 

  23. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19:371–5.

    Article  PubMed  CAS  Google Scholar 

  24. Foon KA, Dougher G. Increased growth of eyelashes in a patient given leukocyte A interferon. N Engl J Med 1984;111:1259.

    Google Scholar 

  25. Deng-Huang S, Ying-Chun C, Shu-Lang L, Tien Chun C. Lanreotide treatment in a patient with interferon-associated Graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthal 2005;243(3):269–72.

    Article  Google Scholar 

  26. Borgia G, Reynaud L, Gentile I, et al. Myasthenia gravis during low dose IFN alpha therapy for chronic hepatitis C. J Interferon Cytokine Res 2001;21:469–70.

    Article  PubMed  CAS  Google Scholar 

  27. Gaspari AA, Lotze MT, Rosenberg SA, et al. Dermatologic changes associated with interleukin 2 administration. J Am Med Assoc 1987;258(12):1624–9.

    Article  CAS  Google Scholar 

  28. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2008;65(5):240–61.

    Article  Google Scholar 

  29. Kumar K, Kochipillai V. Mitoxantrone induced hyperpigmentation. N Z Med J 1990;103:55.

    PubMed  CAS  Google Scholar 

  30. Leyden MJ, Sullivan JR, Cheng ZM, et al. Unusual side effect of mitoxantrone. Med J Aust 1983;2(10):514.

    PubMed  CAS  Google Scholar 

  31. Berkow JW, Gills JP, Wise JB. Depigmentation of eyelids after topically administered thiotepa. Arch Ophthalmol 1969;82:415–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Ophthalmology and Otolaryngology and Head and Neck Surgery, Casey Eye Institute and Devers Eye Institute, Oregon Health Sciences University, Portland, OR, USA

    John D. Ng

Authors
  1. John D. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John D. Ng .

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, Section of Ophthalmology, The University of Texas, Houston, 77030, Texas, USA

    Bita Esmaeli

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ng, J.D. (2010). Orbital and Periorbital Side Effects of Chemotherapy. In: Esmaeli, B. (eds) Ophthalmic Oncology. M.D. Anderson Solid Tumor Oncology Series, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0374-7_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0374-7_27

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-0373-0

  • Online ISBN: 978-1-4419-0374-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation